About — Tirzepatide Research Digest

About this site

Telehealth Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

This site's name references the telehealth context in which tirzepatide is frequently discussed — it is commonly initiated through telemedicine consultations. That is an editorial framing of the research landscape, not a claim that this site provides telehealth services or connects users with prescribers. It does not.

The content on this site draws exclusively from peer-reviewed journals, clinical trial registrations, and authoritative regulatory publications. Every quantitative claim is cited to a specific study listed on the references page. No content is written by or on behalf of any pharmaceutical manufacturer, clinic, pharmacy, or telehealth provider.

Tirzepatide is an FDA-approved prescription medicine. Questions about whether it is appropriate for a specific person — dosing, contraindications, monitoring, drug interactions — belong in a conversation with a licensed clinician. Nothing on this site constitutes medical advice, diagnosis, or a recommendation for any course of action.

What this site covers

This site summarizes the published SURPASS and SURMOUNT phase 3 clinical trial programmes, the pharmacology and mechanism literature, post-market safety data, and relevant systematic reviews and network meta-analyses. The weight-management lens — the primary focus of this digest — reflects the SURMOUNT programme's findings in adults with obesity, which are the most extensively characterized outcomes in the drug's clinical history.

All primary sources are linked from the Tirzepatide references page. Readers who wish to read the primary literature are encouraged to follow those links directly to PubMed, the NEJM, JAMA, and other journals where the trials are published.